Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.44 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CPT1A | P50416 | 2/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514665 | 0.97 | TRPV1 (0.48) | TRPV1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL3510898 | 0.90 | MAPT (0.49) | TRPV1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL3510644 | 0.83 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2NAA50GAA | |
| SCHEMBL3510544 | 0.82 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NAA50GAA | |
| SCHEMBL5645605 | 0.80 | TRPV1 (0.46) | TRPV1RAB9ASMN1; SMN2POLBCPT1A | |
| SCHEMBL475512 | 0.80 | TRPV1 (0.46) | TRPV1RAB9ASMN1; SMN2POLBCPT1A | |
| SCHEMBL12503519 | 0.78 | POLB (0.70) | NPC1RAB9ASMN1; SMN2POLBPREP | |
| SCHEMBL166687 | 0.78 | CPT2 (0.50) | TRPV1SMN1; SMN2POLBNAA50CPT1A | |
| SCHEMBL3511378 | 0.78 | HCRTR1 (0.43) | POLBAADATPREPFAPGAA | |
| SCHEMBL164419 | 0.78 | CPT2 (0.50) | TRPV1SMN1; SMN2POLBNAA50CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2012-08-23 | — | — | US | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, GSAP | TRPV1 4383/4885NPC1 945/4885RAB9A 1919/4885 |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | TRPV1 4577/4885NPC1 934/4885RAB9A 1641/4885 |
| US-20120214802-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | TRPV1 4577/4885NPC1 934/4885RAB9A 1641/4885 |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | TRPV1 3650/4885NPC1 219/4885RAB9A 2364/4885 |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | TRPV1 4577/4885NPC1 934/4885RAB9A 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.